Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2018 1
2021 1
2022 1
2023 2
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND; EMBARK Study. Freedland SJ, et al. Among authors: tutrone rf jr. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.
Lenz L, Clegg W, Iliev D, Kasten CR, Korman H, Morgan TM, Hafron J, DeHaan A, Olsson C, Tutrone RF Jr, Richardson T, Cline K, Yonover PM, Jasper J, Cohen T, Finch R, Slavin TP Jr, Gutin A. Lenz L, et al. Among authors: tutrone rf jr. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):427-434. doi: 10.1038/s41391-024-00888-y. Epub 2024 Sep 5. Prostate Cancer Prostatic Dis. 2025. PMID: 39237680 Free PMC article.
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF Jr, Venugopal B, Woo HH, Ramirez-Backhaus M, Tarazi J, Tang Y, Ganguli A, Haas GP, Shore ND. Freedland SJ, et al. Among authors: tutrone rf jr. Future Oncol. 2025 Feb;21(5):501-514. doi: 10.1080/14796694.2024.2426425. Epub 2024 Dec 12. Future Oncol. 2025. PMID: 39667819 Free PMC article.
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Kalac M, Sridharan S, Rosales M, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Wang F, Freedland SJ. Shore ND, et al. Among authors: tutrone rf jr. N Engl J Med. 2025 Oct 19. doi: 10.1056/NEJMoa2510310. Online ahead of print. N Engl J Med. 2025. PMID: 41124201